Date	Price Target	Rating	Analyst
6/13/2024	$6.00 → $1.00	Buy → Hold	Stifel
6/13/2024	$10.00 → $1.00	Buy → Hold	Canaccord Genuity
6/13/2024		Buy → Hold	Needham
6/13/2024		Buy → Neutral	H.C. Wainwright
3/8/2023	$13.00 → $6.00	Neutral → Underperform	BofA Securities
3/8/2022	$17.00 → $20.00	Neutral → Overweight	JP Morgan
11/1/2021	$33.00	Buy	Canaccord Genuity
8/24/2021	$33.00 → $35.00	Buy	HC Wainwright & Co.

More analyst ratings

$CARA
Press Releases

Fastest customizable press release news feed in the world

Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics
STAMFORD, Conn., April 14, 2025 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) (the "Company"), today announced that its Board of Directors (the "Board") has approved a 1-for-3 reverse stock split of its outstanding shares of common stock. Cara's common stock is expected to begin trading on a reverse stock split-adjusted basis at the opening of the market on Wednesday, April 16, 2025 under the new name "Tvardi Therapeutics, Inc." and under the new symbol "TVRD" following the anticipated closing of the merger (the "Merger") with Tvard Therapeutics, Inc. ("Tvardi"), with a new CUSIP number 140755 307. The reverse stock split was approved by Cara's stockholders at Cara's special
4/14/25 11:50:29 AM ET
$CARA
Biotechnology: Pharmaceutical Preparations
Health Care
Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split
STAMFORD, Conn., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) (the "Company"), today announced that a 1-for-12 reverse stock split of its outstanding shares of common stock and reduction in the total number of authorized shares of its common stock from 200,000,000 to 16,666,667 will be effective as of 5:00 p.m. Eastern Time on Monday, December 30, 2024. The Company's common stock will begin trading on a reverse stock split-adjusted basis at the opening of the market on Tuesday, December 31, 2024. Following the reverse stock split, the Company's common stock will continue to trade on the Nasdaq Capital Market under the symbol "CARA" with the new CUSIP number, 1
12/27/24 7:00:00 AM ET
$CARA
Biotechnology: Pharmaceutical Preparations
Health Care
Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement
Proposed Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company developing novel treatments targeting STAT3 to treat fibrosis-driven diseases Tvardi has recently completed an approximately $28 million private financing, which, together with Tvardi's existing cash and Cara's anticipated cash balance, is expected to fund the combined company into the second half of 2026 Tvardi anticipates reporting topline data in the second half of 2025 from two Phase 2 clinical programs utilizing its STAT3 inhibitor, TTI-101, including its lead program in idiopathic pulmonary fibrosis and its program in hepatocellular carcinoma Companies to hos
12/18/24 7:00:00 AM ET
$CARA
Biotechnology: Pharmaceutical Preparations
Health Care

FDA Approval for KORSUVA issued to CARA THERAPEUTICS INC

Products on NDA 214916

Approval Date(s) and History, Letters, Labels, Reviews for NDA 214916

Original Approvals or Tentative Approvals

Therapeutic Equivalents for NDA 214916

KORSUVA

Chat with this insight

Recent Analyst Ratings for $CARA

$CARA Press Releases

Fastest customizable press release news feed in the world

Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics

Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split

Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement

Recent Analyst Ratings for
$CARA

$CARA
Press Releases